Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10(7):1171-5.

Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich TK, Largiader CR, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2013;71(2):361-70.

Abdel-Rahman O. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019;18(2):110-115.

Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117-25.

Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D et al. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. Eur J Cancer. 2018;99:66-77.

Fluorouracil Accord (fluorouracil). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-12-16, cited 2021-06-03]

Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]